RIST4721 is an oral CXC chemokine receptor 2 (CXCR2) antagonist being developed as a treatment for palmoplantar pustulosis (PPP), and possibly other neutrophil-mediated diseases. Aristea inked an up-to-$70 million strategic collaboration with Arena Pharmaceuticals to advance RIST4721, through which Arena agreed to pay Aristea $60 million upfront and invest $10 million equity toward a $63 million Series B financing also completed by the San Diego biotech . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge